Embecta Corp.

NasdaqGS EMBC

Embecta Corp. Net Income Margin for the Trailing 12 Months (TTM) ending December 31, 2024: 5.19%

Embecta Corp. Net Income Margin is 5.19% for the Trailing 12 Months (TTM) ending December 31, 2024, a 5.36% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Embecta Corp. Net Income Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was 4.93%, a -65.64% change year over year.
Embecta Corp. Net Income Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was 14.34%, a -58.97% change year over year.
Embecta Corp. Net Income Margin for the Trailing 12 Months (TTM) ending December 31, 2021 was 34.94%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: EMBC

Embecta Corp.

CEO	Mr. Devdatt Kurdikar
IPO Date	March 22, 2022
Location	United States
Headquarters	300 Kimball Drive
Employees	2,200
Sector	Healthcare
Industries Pharmaceuticals Drugstores & Retail Pharmacies Eyewear Medical Instruments Non-Alcoholic Beverages Personal Care Snack Foods Soft Drinks & Sodas

Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Key trends

Past 5 years